Logo image of IMMP

IMMUTEP LTD-SP ADR (IMMP) Stock Fundamental Analysis

USA - NASDAQ:IMMP - US45257L1089 - ADR

2.01 USD
-0.02 (-0.99%)
Last: 10/10/2025, 9:35:44 PM
2.08 USD
+0.07 (+3.48%)
After Hours: 10/10/2025, 9:35:44 PM
Fundamental Rating

3

Taking everything into account, IMMP scores 3 out of 10 in our fundamental rating. IMMP was compared to 537 industry peers in the Biotechnology industry. While IMMP seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, IMMP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IMMP had negative earnings in the past year.
In the past year IMMP has reported a negative cash flow from operations.
In the past 5 years IMMP always reported negative net income.
In the past 5 years IMMP always reported negative operating cash flow.
IMMP Yearly Net Income VS EBIT VS OCF VS FCFIMMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

IMMP's Return On Assets of -24.06% is fine compared to the rest of the industry. IMMP outperforms 74.30% of its industry peers.
IMMP has a Return On Equity of -25.43%. This is amongst the best in the industry. IMMP outperforms 80.63% of its industry peers.
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROIC N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
IMMP Yearly ROA, ROE, ROICIMMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

IMMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMMP Yearly Profit, Operating, Gross MarginsIMMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K -100K

More info and screens

6

2. Health

2.1 Basic Checks

IMMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMMP has less shares outstanding than it did 1 year ago.
The number of shares outstanding for IMMP has been increased compared to 5 years ago.
The debt/assets ratio for IMMP is higher compared to a year ago.
IMMP Yearly Shares OutstandingIMMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
IMMP Yearly Total Debt VS Total AssetsIMMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 24.32 indicates that IMMP is not in any danger for bankruptcy at the moment.
IMMP has a Altman-Z score of 24.32. This is amongst the best in the industry. IMMP outperforms 92.74% of its industry peers.
IMMP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
IMMP's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. IMMP outperforms 47.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.32
ROIC/WACCN/A
WACC9.68%
IMMP Yearly LT Debt VS Equity VS FCFIMMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
With an excellent Current ratio value of 18.86, IMMP belongs to the best of the industry, outperforming 93.30% of the companies in the same industry.
A Quick Ratio of 18.86 indicates that IMMP has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 18.86, IMMP belongs to the best of the industry, outperforming 93.30% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.86
Quick Ratio 18.86
IMMP Yearly Current Assets VS Current LiabilitesIMMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

IMMP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.43%.
Looking at the last year, IMMP shows a very negative growth in Revenue. The Revenue has decreased by -49.75% in the last year.
IMMP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -66.35% yearly.
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%

3.2 Future

Based on estimates for the next years, IMMP will show a very strong growth in Earnings Per Share. The EPS will grow by 75.20% on average per year.
The Revenue is expected to grow by 123.43% on average over the next years. This is a very strong growth
EPS Next Y-25.63%
EPS Next 2Y-11.81%
EPS Next 3Y25.84%
EPS Next 5Y75.2%
Revenue Next Year1.99%
Revenue Next 2Y-27.58%
Revenue Next 3Y180.85%
Revenue Next 5Y123.43%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMMP Yearly Revenue VS EstimatesIMMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
IMMP Yearly EPS VS EstimatesIMMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IMMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMMP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMMP Price Earnings VS Forward Price EarningsIMMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMMP Per share dataIMMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as IMMP's earnings are expected to grow with 25.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.81%
EPS Next 3Y25.84%

More info and screens

0

5. Dividend

5.1 Amount

IMMP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUTEP LTD-SP ADR

NASDAQ:IMMP (10/10/2025, 9:35:44 PM)

After market: 2.08 +0.07 (+3.48%)

2.01

-0.02 (-0.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-29 2025-08-29/bmo
Earnings (Next)02-24 2026-02-24
Inst Owners40.58%
Inst Owner Change0.08%
Ins Owners2.13%
Ins Owner ChangeN/A
Market Cap292.37M
Analysts82.22
Price Target2.35 (16.92%)
Short Float %3.03%
Short Ratio51.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.56%
PT rev (3m)4.26%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.59%
EPS NY rev (3m)-15.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)25.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8291.52
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.78
TBVpS0.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.06%
ROE -25.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.13%
ROA(5y)-31.07%
ROE(3y)-31.51%
ROE(5y)-33.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 1556.13%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.86
Quick Ratio 18.86
Altman-Z 24.32
F-Score2
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.44%
EPS Next Y-25.63%
EPS Next 2Y-11.81%
EPS Next 3Y25.84%
EPS Next 5Y75.2%
Revenue 1Y (TTM)-49.75%
Revenue growth 3Y-38.18%
Revenue growth 5Y-66.35%
Sales Q2Q%-18.07%
Revenue Next Year1.99%
Revenue Next 2Y-27.58%
Revenue Next 3Y180.85%
Revenue Next 5Y123.43%
EBIT growth 1Y-12.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.65%
EBIT Next 3Y34.14%
EBIT Next 5Y19.8%
FCF growth 1Y-10.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A